---
title: Retrospective Study on the Use of CEFALY® Device During Migraine Attacks
nct_id: NCT02616978
overall_status: COMPLETED
sponsor: Cefaly Technology
study_type: OBSERVATIONAL
primary_condition: Migraine
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02616978.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02616978"
ct_last_update_post_date: 2017-05-08
last_seen_at: "2026-05-12T06:46:04.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Retrospective Study on the Use of CEFALY® Device During Migraine Attacks

**NCT ID:** [NCT02616978](https://clinicaltrials.gov/study/NCT02616978)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 807
- **Lead Sponsor:** Cefaly Technology
- **Conditions:** Migraine
- **Start Date:** 2015-11
- **Completion Date:** 2015-12
- **CT.gov Last Update:** 2017-05-08

## Brief Summary

This is an Internet survey to collect data on the use of the Cefaly device to treat migraine attacks in regular Cefaly users.

## Detailed Description

About 1000 CEFALY users, having the device since more than one year and having reordered electrodes in the last year, will be invited to participate to an Internet survey. This survey contains at most 8 questions, and data will be collected completely anonymously. Questions concern the use or not of the CEFALY during migraine attacks, the number of treated attacks and the number and type of acute anti-migraine drugs that were avoided thanks to the use of the CEFALY.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects using Cefaly device regularly for more than a year identify by reordering of electrodes during the last year.
* History of likely episodic or chronic migraine with or without aura diagnosed by a physician

Exclusion Criteria:

* N/A
```

## Primary Outcomes

- **Monthly number of acute drug intake avoided when using Cefaly to treat a migraine attack** _(time frame: Maximum 1 year)_ — On average, mean number of anti-migraine acute drug intake avoided per month per patient in regular Cefaly users, based on self reported average monthly number of attacks and percentage of attacks treated successfully with the Cefaly

## Secondary Outcomes

- **Proportion of Cefaly users that report using also the device to treat migraine attacks** _(time frame: Maximum 1 year)_
- **Proportion of migraine attacks treated with the Cefaly device** _(time frame: Maximum 1 year)_
- **Proportion of migraine attacks for which the use of the Cefaly device generate a reduction of drug intake** _(time frame: Maximum 1 year)_

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02616978.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02616978*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*